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Abstract
Background Large numbers of translational breast cancer
research topics have been completed or are underway, but they
differ widely in their immediate and/or future importance to
clinical management. We therefore conducted an international
Web-based consultation of breast cancer professionals to
identify the topics most widely considered to be of highest
priority.
Methods Potential participants were contacted via two large e-
mail databases and asked to register, at a Web site, the issues
that they felt to be of highest priority. Four hundred nine
questions were reduced by a steering committee to 70 unique
issues, and registrants were asked to select the 6 questions
they considered to be the most important.
Results Votes were recorded from 420 voters (2,520 votes)
from 48 countries, with 48% of voters coming from North
America. Half of the voters identified themselves as clinicians,
with the remainder being academics, research scientists, or
pathologists. The highest priority was to identify molecular
signatures to select patients who could be spared
chemotherapy, which gained about 50% more votes than the
second topic and was consistently voted top by voters in North
America, Europe, and the rest of the world. Research scientists
voted the determination of the role of stem cells in breast cancer
development, progression, and treatment sensitivity as the most
important issue, but this was considered the sixth priority for
clinicians and fourth overall.
Conclusion This exercise may bring a greater focus of research
resources onto issues voted as top priorities.
Introduction
In recent years, there has been a major increase in the appli-
cation of new scientific tools and knowledge to tissues and
fluid samples from patients with cancer in an attempt to better
understand the biology of the disease and the consequences
that this biology may have for prognosis and response to treat-
ment. The potential importance of this for increasing the indi-
vidualisation of treatment is now sufficiently well recognised
that few clinical trials are initiated without collection of tissues/
fluids for future analysis, irrespective of the development of a
hypothesis at the time. Of the solid tumours, breast cancer has
received the greatest attention in this pursuit of translational
research, and a number of resultant highly cited articles have
affected our view of the disease [1,2].
It is clear, however, that although the new technologies such
as expression array profiling are powerful tools, their untar-
geted application is likely to be a missed opportunity for deliv-
ering important clinical advances. Translational research
frequently reflects the immediate scientific interests of the
investigators and the specimens available to them as opposed
to a specific attempt to address a question that has been
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identified as having the potential to advance the management
of patients. The identification of high-priority questions for the
breast cancer research community may be better obtained by
wide consultation within that community than by local opinion
based on the challenges posed and opportunities available to
individual investigator groups. Such identification might result
in a prioritisation of the respective issue in terms of research
activity, funding priority, peer-reviewed publications, and sym-
posia presentations.
The project reported here involved an international Web-
based consultation of breast cancer practitioners and
researchers in which opinion was sought to identify an initial
set of topics/questions perceived to be of high importance.
Voting was then conducted to determine a consensus position
on the importance of the questions. The project was named
the Top Ten program and arbitrarily gave particular emphasis
to those 10 topics/questions receiving the most votes.
Materials and methods
A steering committee composed of the authors of this paper
was created to form a key advisory group on the format and
execution of the consultation. An interactive Web site was
developed [3] to allow participants to register and participate
in the consultation. The program had the following key stages.
a. A primary target database of more than 4,000 potential par-
ticipants was developed by consolidation of the contact e-mail
addresses of registrants at the 2005 San Antonio Breast Can-
cer Symposium and the 2005 St Gallen Consensus Meeting
on Primary Therapy of Early Breast Cancer. A letter describing
the activity as 'a global program to identify the most important
questions for the breast cancer community in the area of trans-
lational research' was e-mailed to members on the database in
October 2006, inviting them (and any of their colleagues) to
register on the Web site and contribute their own priorities for
research with a view to voting later on a consolidated list. They
were informed that the two-stage process was expected to
take them no more than 20 minutes. It was declared that the
list of the top ten priorities would be announced at the St Gal-
len Consensus Meeting in March 2007 and that a simultane-
ous announcement on the Web site would occur. All
registrants would later receive a fuller report on the activity and
its results. Registration required a contact e-mail address;
identification as a clinician, pathologist, research scientist, or
academic; and current home country. The list of registered pri-
orities was cumulative and could be viewed by later registrants
who were asked to examine the earlier list and place only pre-
viously unlisted issues. Logging of topics/questions ceased on
3 November 2006.
b. The steering committee reviewed the listings and created a
consolidated list in two phases: (i) exclusion of issues that
were not translational in their orientation or that were a clear
duplication of another issue and (ii) reduction of markedly
overlapping priorities to single unique topics.
c. On 8 January 2007, registrants were contacted again by e-
mail to invite them to revisit the Web site and place their votes
on the consolidated list of priorities on the Web site. Six votes
in order of priority were required. Voting ceased on 9 February
2007.
d. Votes were counted and allocated scores as follows: top
priority, 6 points; second priority, 5 points; third priority, 4
points; fourth priority, 3 points; fifth priority, 2 points; and sixth
priority, 1 point. The scores were summed for each of the top-
ics to create the consensus scoring. Descriptive analyses
were performed to determine the relationship between profes-
sion and region with voting pattern.
e. The top ten priorities were announced at the St Gallen Con-
sensus Meeting on 17 March 2007 and simultaneously on the
Web site.
Results
Four hundred and nine topics were logged by registrants but
many were overlapping, and it was clear to the steering com-
mittee that the request to registrants to record only those top-
ics that had not been previously logged was not fully adhered
to. The initial consolidation to exclude topics that were clearly
duplicated or that were not of a translational research nature
reduced the number to 139. The aim and expectation of the
steering committee had been to consolidate this further to no
more than 30 unique topics. However, it became clear that it
was not possible to reduce the number below 70 without com-
plete exclusion of certain topics, which would have been con-
trary to one of the main goals of the project, namely to draw on
widespread opinion unaffected by steering committee views.
The full set of 70 questions is listed in Supplementary Table
S1 (Additional File 1), which includes the categorisation (for
example, chemotherapy, radiotherapy, and prognosis) that
was designated to them.
Four hundred twenty registrants voted on the 70 topics. One
hundred seventy-eight were from the US and a further 22 were
from Canada, making a total of 48% of respondents being
from North America. One hundred thirty-three (32%) were
from Europe and the remaining 84 (20%) were from the rest
of the world (RoW), with Japan making up the largest group.
Registrants from a total of 48 countries voted. Two hundred
nine (50%) of the registrants classed themselves primarily as
clinicians, 101 (24%) as academics, 86 (20%) as research
scientists, 14 (3%) as pathologists, and 10 registrants did not
fit any of these categories. Whereas the proportions of
research scientists and pathologists were relatively similar
between North America and Europe, the proportions of aca-
demics and clinicians were not: in North America theAvailable online http://breast-cancer-research.com/content/9/6/R81
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proportions were 39% and 36%, respectively, and in Europe
they were 59% and 71%, respectively.
The emphasis in this consultation was on the top ten priorities,
but the focus on 10 was arbitrary, so the list of the top 15 is
given in Table 1, together with the number of points scored.
The weighting of each person's votes with 6 points downward
to 1 point was also arbitrary. To ensure that this did not cause
biases in the overall ranking, we also ranked the topics accord-
ing to the number of votes cast irrespective of the order they
were ranked in by individual voters and also according to the
number of times the topic appeared as the top of individual
rankings. These two alternate approaches had virtually no
effect on the outcome and therefore are not presented. A his-
togram showing the overall voting pattern for the 70 questions
based on the weighted points system is shown in Figure 1.
Table 1 shows that the top topic overall – with about 50%
more voting points than any other – was to identify molecular
signatures to select patients who could be spared chemother-
apy. This was also the top question for each of the three
regions of North America, Europe, and RoW (Figure 2). Clini-
cians rated this as clearly the top issue (Figure 3), but academ-
ics rated the overall second topic (to identify molecular
features that indicate the optimal chemotherapy regimen) as
only 1 point behind the No. 1 choice (123 points versus 122).
Research scientists rated the overall No. 4 choice (to deter-
mine the role of stem cells in breast cancer development, pro-
gression, and treatment sensitivity) as the top question, with
136 votes versus 114 votes for the overall top question on the
need for chemotherapy. This stem cell question was sixth in
order of priority for the clinicians, third for the academics, and
fourth overall.
Figures 2 and 3, respectively, reveal that geographic region of
voting had only a modest effect on the voting pattern but that
the professional discipline of the voter appeared to have a
more marked influence, with substantial variation between the
Table 1
The top 15 research questions/topics
Final rank Topic category Research question/topic Total points received
1 Chemotherapy Identify molecular signatures to select patients who could be spared 
chemotherapy
643
2 Chemotherapy Identify molecular features that indicate the optimal chemotherapy regimen (for 
example, combination or sequential, anthracyclin or not, and taxane or not)
450
3 DCIS Determine the factors in DCIS and/or atypical ductal hyperplasia which lead to 
progression into invasive carcinoma
406
4 Stem cells Determine the role of stem cells in breast cancer development, progression, and 
treatment sensitivity
404
5 Triple-negative/basal Identify response/resistance mechanisms and thereby therapeutic targets for 
triple-negative breast cancer
369
6 Computing Develop a system (computer and so on) that will integrate all the information 
gathered so far about breast cancer to build robust models for understanding the 
aetiopathogenesis, treatment, and prognosis of breast cancer
305
7 Prognosis Identify which low-risk patients require no adjuvant therapy 301
8 New growth factor targets Determine whether other growth factor pathways (such as epidermal growth 
factor receptor, insulin-like growth factor receptor, Notch, Hedeghog, Wnt, and 
other angiogenic pathways) are important targets for therapy
287
9 Genetics Investigate which gene mutations in a tumour lead to metastases 236
10 Endocrine Identify drugable targets that can be developed/exploited for therapeutic gain to 
overcome primary/secondary endocrine resistance
226
11 Consensus Define consensus phenotyping procedures for specific molecular subtypes of 
breast cancer (immunohistochemistry, expression array, or reverse transcription-
polymerase chain reaction signature genes)
201
12 Endocrine Search for a more accurate and validated score of hormone sensitivity 180
13 (tie) Imaging Develop non-invasive techniques to diagnose and characterise primary breast 
tumours
171
13 (tie) Endocrine Determine whether there is a molecular profile (including PgR and HER2) that 
can distinguish patients likely to respond to tamoxifen versus an aromatase 
inhibitor
171
15 Herceptin: duration Identify markers of the optimal duration of trastuzumab therapy 165
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clinicians and the research scientists and, to a lesser degree,
between the clinicians and the academics. An insufficient
number of pathologists participated to assess these as a
meaningful subgroup. At the bottom of the list of 70 priorities
were two prognostic questions, one on the importance of
young age and the other on the difference between lymphatic
invasion and nodal status as prognostic factors.
Discussion
In recent years, the interest in applying the results of laboratory
studies to advance the treatment of breast cancer has
increased substantially in so-called translational research.
While this is a welcome development, there has been very
wide targeting of resources. This may be based on many rea-
sons, including the local opportunities available and a consid-
eration of the most relevant/important questions to an
individual's research. The rationale of the present study was
that a wide consultation to identify priority questions in trans-
lational breast cancer research might help investigators, fund-
ing agencies, and journal reviewers/editors to prioritise their
resources to address the most pressing clinical questions. The
documentation of the questions widely considered to be of
high priority may lead investigators to review the priority of
their own research in part because such research may be seen
by funding agencies as more worthy of support and high-
impact journals may be more likely to accept it for publication.
In discussions before and during the project, the majority of
consulted specialists felt the idea very worthwhile but a
minority had strong reservations on a number of fronts. These
included the possibility of voting being influenced by what is
fashionable but of little real importance and also the possibility
that, if this process did influence the research agenda, it might
lead to the suppression of novel, but potentially highly impor-
tant, ideas that inevitably would not feature in most voters'
thoughts. The former of these issues probably can be
addressed only by the passage of time, but the latter may be
avoided by recognition of the possibility and an open-minded-
ness to new ideas/concepts as well as maintaining a focus on
present priorities.
The use of the San Antonio and St Gallen e-mail databases as
the primary contact sources aimed to achieve worldwide inter-
est and voting, given the predominance of North American par-
ticipants in San Antonio and of participants from other parts of
the world (particularly Europe) in St Gallen. The results of the
request for priority questions supported our starting position
that there is a very wide opinion of what is important, given that
more than 130 individual questions were logged and that
these could be reduced by the steering committee to only 70
unique consolidated topics. It is important to consider whether
420 registrant voters is sufficient to provide a representative
guide to worldwide opinion: this is supported by the similar
voting patterns from the three geographical regions, with the
top question being the same for all three and only minor varia-
tion existing between them for the other top issues.
Professional group appeared to influence voting more sub-
stantially. The stem cell question (No. 4 overall) gained only
151 points from clinicians compared with 391 for the topic of
identifying patients who could avoid chemotherapy. In con-
trast, the respective points from research scientists were 136
and 114. These votes seem to be weighted according to the
degree of interest in the topic for the respective professional
group, the chemotherapy question being one that challenges
clinicians on a frequent basis but that attracts less attention
from scientists. The stem cell issue might be seen, particularly
by scientists, as of central future importance to the progress in
clinical breast cancer research. While this topic was not rated
as unimportant by clinicians, the lower likelihood of its deliver-
ing clinically influential data in the near future might lead to its
being considered less important.
It could be argued that if translational research is to be tar-
geted by processes such as this consultation, the opinions of
clinicians should be given greater weighting since it is they
who will be directly challenged by the issues on a regular
basis; the views of other specialists would be likely to be influ-
enced by other factors unrelated to clinical importance. An
examination of Figure 3 shows that such weighting was not
necessary in this process since the clinician votes were rather
similar to the overall voting pattern. It also seems likely that
even without specifically creating a weighting, the use of two
large e-mail listings from largely clinically orientated interna-
tional meetings for making primary contacts will have resulted
in a much larger proportion of clinician responses than if more
general listings had been used.
Figure 1
Distribution of votes overall among the 70 questions, showing the clear  distinction of the highest priority Distribution of votes overall among the 70 questions, showing the clear 
distinction of the highest priority. The identities and point allotments of 
the questions are presented in Supplementary Table S1 (Additional 
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The goal of identifying molecular signatures to select patients
who could be spared chemotherapy being the top priority is
likely to reflect the widespread recognition of the very good
prognosis of patients diagnosed with breast cancer in recent
years. This has resulted from earlier diagnosis largely as a
result of screening and the major impact of the widespread
application of hormone therapies to patients with oestrogen
receptor-positive disease [4]. Thus, there is a large proportion
of patients for whom any benefit in outcome as a result of adju-
vant chemotherapy is likely to be so small as to be outweighed
by concomitant toxic side effects. The voting for this topic sup-
ports the efforts of the TAILORx (Trial Assigning Individualized
Options for Treatment [Rx]) and MINDACT (Microarray In
Node-negative Disease may Avoid ChemoTherapy) investiga-
tors, who are investigating the clinical significance of the appli-
cation of the OncotypeDX and MammoPrint molecular
signatures, respectively [5,6].
In contrast, there are fewer well-publicised studies aimed at
addressing the second most important topic, namely of identi-
fying molecular features to select the optimal chemotherapy
regimen. One of the issues here is that, while molecular signa-
tures to address prognosis can be derived using samples from
non-randomised sources, this second topic requires the
assessment of large sample sets from clinical trials randomis-
ing different chemotherapy regimens. Collections of such tis-
sues have only recently become the norm, so it is only in the
last few years that we have achieved the ability to address
what in reality is a series of questions on the comparison of
multiple different regimens, one against the other. It should
also be recognised that unless there is a very large difference
between treatment effectiveness according to molecular sub-
type, a significant statistical interaction with treatment out-
come is unlikely. The establishment of a good understanding
of mechanisms of response and resistance to particular
regimens in laboratory studies is likely to provide the greatest
opportunity for providing such markers.
The third choice in the list of priorities was the goal of identify-
ing factors in ductal carcinoma in situ and/or atypical ductal
hyperplasia which lead to progression to invasive cancer. In
common with the first priority, this can be viewed as attempt-
ing to identify patients who can avoid major therapy. The stem
cell question (at No. 4) has been discussed above. The fifth
priority – identifying the response and resistance mechanisms
related to triple-negative/basal tumours – is one that itself has
emanated from translational research in that the first expres-
sion array studies of breast cancer samples led to the identifi-
cation of this group as an entity with poor prognosis and
limited response to conventional therapies [1,7]. This is a clear
Figure 2
Distribution of votes for the top 10 topics by region of the world: (a) overall, (b) North America, (c) Europe, and (d) the rest of the world Distribution of votes for the top 10 topics by region of the world: (a) overall, (b) North America, (c) Europe, and (d) the rest of the world. The identity 
of each topic can be found by referring to the identical numbering in Table 1.Breast Cancer Research    Vol 9 No 6    Dowsett et al.
Page 6 of 7
(page number not for citation purposes)
example of the two-way nature of translational research, from
the clinic to the laboratory and back to the clinic.
To address each of these topics in an instructive fashion, it is
essential that there be close adherence to principles of good
practise for translational research: (a) a clear understanding
and declaration of the question to be addressed, (b) the selec-
tion of tissue sample sets suitable for directly addressing the
question, (c) the application of well-validated reagents and
methodologies to tissue samples characterised as being of
high quality, (d) the linkage of the samples to accurate clinical
information in cases in which the topic relates to clinical
outcome (which it does in almost all of the top-priority cases),
and (e) the testing of sufficiently numerous samples to meet
prospectively derived statistical power calculations. If any of
the above guidelines are not met, the study should be declared
as hypothesis-generating. If the study does not select markers
based on declared hypotheses, the initial study should be rec-
ognised as a training set, which requires validation on at least
one appropriate, independent test set. The conclusions from
these studies should be recognised as being applicable only
within the populations studied (for example, with respect to
age, menopausal status, and tumour size) unless subjected to
further study to establish that the results may be generalised.
Finally, to find its place in clinical practise, the new test may
require prospective evaluation of its impact on clinical
outcome.
The success and importance of the present exercise are diffi-
cult to judge but may be measured in part by citations of this
article or the presentations of the results at the St Gallen meet-
ing. This will determine whether it is repeated in the coming
years, as there is no doubt that priorities will change with time.
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